San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.
South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
